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Human immunodeficiency virus type 1 (HIV-1) Tat transcriptionally activates expression from a number of viral and cellular
promoters. Recent studies demonstrate the ability of Tat to differentially modulate cellular responses to apoptotic signaling. The
antiapoptotic effects of Tat appear to correlate with increased expression of Bcl-2, a cellular protein that enhances cellular survival.
Here, endogenous expression of HIV-1 Tat in HeLa and Jurkat cells elevates levels of Bcl-2. Transient expression assays
performed in HeLa cells demonstrate that Tat directly or indirectly enhances Bcl-2 promoter-directed gene expression by more
than 10-fold. Analyses of Tat mutants demonstrate that two noncontiguous regions in the N- and C-termini of Tat mediate maximal
transactivation of the Bcl-2 promoter. The requirement for C-terminal sequences contrasts with transactivation of the HIV-1 long
terminal repeat in which the N-terminal 57 amino acids are required but downstream residues are not. Bcl-2 promoter analyses
suggest that sequences required for Tat responsiveness are located upstream of P1 and between the P1 and P2 promoter units.
Results from these studies reveal effects of HIV-1 Tat on Bcl-2 expression and provide a putative mechanism by which
endogenously expressed Tat affects cellular survival through the up-regulation of Bcl-2. © 1999 Academic Pressa
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iINTRODUCTION
Tat is a regulatory protein encoded by human immuno-
eficiency virus type 1 (HIV-1) that is essential for HIV-1
ene expression and replication (Cullen, 1998). The pre-
ominant and most potent functional role of Tat is as a
ranscriptional transactivator (Cullen, 1998). Tat stimulates
IV-1 transcriptional activation through an RNA response
lement (TAR) to which it binds, located within the 59-
ntranslated leader sequences of all HIV-1 mRNAs
Cullen, 1998). Tat transactivates transcription in a TAR-
ependent manner from the HIV-1 promoter [long termi-
al repeat (LTR)]. Recent discoveries of a functional as-
ociation of critical cellular cofactors (CDK9/cyclinT) that
ediate transcriptional activation of the HIV-1 LTR by Tat
uggest a mechanism for TAR-dependent transactivation
Cullen, 1998; Emerman and Malim, 1998; Jeang, 1998;
ones, 1997; Yankulov and Bentley, 1998). However, the
ole of Tat in the activation of several heterologous viral
nd cellular promoters in a TAR-independent manner
emains less clear (Biswas et al., 1995; Buonaguro et al.,
994; Chowdhury et al., 1990, 1992; Cupp et al., 1993;
iLuca et al., 1991; Kim et al., 1993; Nabell et al., 1994;
uri and Agarwal, 1992; Scala et al., 1994; Taylor et al.,
992; Ursini et al., 1993; Westendorp et al., 1994; Wright et
l., 1994; Yang et al., 1997; Zauli et al., 1995).
1 To whom reprint requests should be addressed. Fax: (504) 587-
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502Potentially associated with its role as a transactivator, Tat
ffects cellular survival and growth (Ensoli et al., 1990, 1993;
cCloskey et al., 1997). Consistent with this growth regu-
atory function, the addition of exogenous Tat to T cells
nduces apoptosis, whereas the constitutive expression of
at in T cells protects them from apoptosis (McCloskey et
l., 1997). The ability of Tat to promote cell survival corre-
ates with several other viral proteins, such as adenovirus
1B (Debbas and White, 1993), Epstein–Barr virus LMP-1
Henderson et al., 1991), and baculovirus IAP (Miller, 1997),
hich similarly protect cells from apoptosis induced by a
ide-range of proapoptotic stimuli.
A putative mechanism by which Tat, and possibly
ther similarly acting viral proteins, protect cells from
poptosis may be through the induction of Bcl-2 (Wattre
t al., 1996). In support of this postulate, HIV-1 Tat pro-
ects lymphoid, epithelial, and neuronal cell lines from
eath by apoptosis induced by serum deprivation that
orrelates with increased levels of Bcl-2 within these
ells (Zauli et al., 1993).
Bcl-2 is a member of a gene family that encodes
roteins that either promote or inhibit apoptosis (Yang
nd Korsmeyer, 1996). A number of Bcl-2 family members
ave been identified in mammals, including Bcl-2, Bcl-xL,
cl-1, and Bcl-w, which block apoptosis, and Bax, Bad,
ik, Bak, and Bcl-xS, which induce apoptosis (Nagata,
997). Proapoptotic members, such as Bax and Bak,
ither accelerate programmed cell death or, in some
nstances, induce cell death in the absence of additional
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503TAT TRANSACTIVATION OF Bcl-2ignals. Antiapoptotic members, such as Bcl-2 and Bcl-
L, antagonize programmed cell death induced by a wide
ariety of stimuli, such as irradiation, growth factor de-
rivation, c-myc, and anticancer drugs (Nagata, 1997).
umerous studies suggest that the relative levels of
roapoptotic and antiapoptotic Bcl-2 family member pro-
eins within a cell predicts whether that cell lives or dies
n response to apoptotic signaling. Although many differ-
nt signals induce apoptosis, the downstream biochem-
cal events that lead to cell death appear to be highly
imilar, suggesting that the signals from various initiators
onverge on a common death pathway (Yang and Kors-
eyer, 1996). Because Bcl-2 protects cells from apopto-
is induced by a wide variety of these initiating signals,
t likely functions within this downstream convergent
athway.
The mechanisms that regulate Bcl-2 expression and
unction are, in general, incompletely understood. In-
riguing reports from different experimental systems sug-
est that multiple pathways of Bcl-2 induction exist. Up-
egulation of Bcl-2 and consequent blocking of apoptosis
y viral gene products, with or without cooperative ef-
ects of cytokines, have been described (Geiger et al.,
995; Henderson et al., 1991, 1993; Silin et al., 1995).
ecause viral replication often signals apoptosis, many
iruses, particularly those associated with transforma-
ion, encode Bcl-2-like factors that promote cell survival
nd thereby enhance viral production. As an example, a
unctional Bcl-2 homolog encoded by the human herpes-
irus type-8, which is associated with Kaposi’s sarcoma,
as recently been discovered (Sarid et al., 1997). More-
ver, overexpression of cellular Bcl-2 can be observed in
aposi’s sarcoma (Morris et al., 1996), and prolonged
urvival of Kaposi’s sarcoma cells may account for the
ncogenic characteristics of these cells. Similarly, Ep-
tein–Barr virus also carries a Bcl-2 homolog called
HRF-1 and, in addition, encodes proteins such as
MP-1 that increase the expression of the cellular bcl-2
ene (Henderson et al., 1991, 1993; Silin et al., 1995).
The molecular basis for antagonism of apoptosis in
ells endogenously expressing Tat is not understood.
he hypothesis supported herein is that Tat promotes
ellular survival through the up-regulation of Bcl-2. The
esults from this study demonstrate that constitutive ex-
ression of HIV-1 Tat in HeLa and Jurkat cell lines in-
reases levels of Bcl-2 over that of control cells. In
ransient expression assays, Tat stimulates Bcl-2 pro-
oter-directed gene expression by more than 10-fold.
oth N- and C-terminal sequences of Tat that contain the
ctivation and RGD domains, respectively, are required
or transactivation. Sequences located upstream of P1
nd between the P1 and P2 promoter units of Bcl-2
ediate responsiveness to Tat transactivation. These
tudies demonstrate that endogenous expression of Tat
timulates the expression of Bcl-2 and suggests a mech-nism by which the viability of HIV-1-infected cells may
e sustained to promote viral replication.
RESULTS
onstitutive expression of HIV-1 Tat in HeLa cells
levates Bcl-2 expression
Previous studies have shown that Bcl-2 enhances cell
urvival in vivo and in vitro by blocking programmed cell
eath (Yang and Korsmeyer, 1996). Jurkat T-cells stably
xpressing HIV-1 Tat are resistant to apoptosis (McCloskey
t al., 1997; Zauli et al., 1995), which appears to correlate
ith increased Bcl-2 expression (Zauli et al., 1995).
To test the hypothesis that Tat up-regulates Bcl-2 gene
xpression, lysates from HeLa cells stably transformed
ith a Tat expression plasmid (LTR-Tat) or with a control
lasmid (LTR-CAT) were subjected to Bcl-2-specific
estern blot analyses. The results indicated that Bcl-2
xpression is elevated in cells that constitutively express
at compared with that observed in control cells (Fig. 1),
uggesting that Tat up-regulates endogenous Bcl-2 gene
xpression. However, the observed difference in Bcl-2
xpression in these two isolated cell lines may also be
xplained by other factors (i.e., selection of a subpopu-
ation of cells that has higher basal levels of Bcl-2) that
re independent of Tat expression. To address more
efinitively the ability of Tat to stimulate Bcl-2 expression,
ransient expression assays were performed to deter-
ine whether Tat activates Bcl-2 promoter activity.
IV-1 Tat transactivates Bcl-2 promoter-directed gene
xpression
To determine whether HIV-1 Tat activates Bcl-2 pro-
oter-directed gene expression, a reporter plasmid con-
aining the Bcl-2 promoter cloned immediately upstream
f the chloramphenicol acetyltransferase (CAT) gene
as cotransfected with wild-type or mutant Tat expres-
ion vectors into HeLa or Jurkat cells. Comparisons were
FIG. 1. Increased Bcl-2 expression in HeLa cells constitutively express-
ng Tat. Lanes 1 and 2 contain cell lysates from HeLa cells stably trans-
ormed with an HIV-1 LTR-CAT reporter construct. Lanes 3 and 4 contain
ell lysates from HeLa cells stably transformed with an HIV-1 LTR-Tat
xpression vector. Equal amounts of cell lysates (100 mg) were electro-
horesed in 12% SDS–PAGE. Western blot analyses were performed, and
cl-2-specific bands were detected by chemiluminescence (Bio-Rad).
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504 WANG ET AL.ade between wild-type and mutant forms of Tat. The
utations in Tat not only provided a means to identify
omains of Tat that may be required for transactivation
ut also served to control for specificity of Tat transacti-
ation. CAT assays were performed 48 h after transfec-
ion. Fold activation was calculated as a ratio of aver-
ged CAT activities in the presence of wild-type Tat to
hose in the presence of the activation domain-defective
at mutant, D2-36 (set arbitrarily at a value of 1). The
esults demonstrated that Tat transactivates Bcl-2 pro-
oter-directed CAT expression in HeLa cells (;18-fold;
FIG. 2. Tat activates Bcl-2 promoter-directed CAT expression in HeLa
AT activities in the presence of wild-type Tat over that in the presence
.E.M. in HeLa and Jurkat cells was 17.9 6 3 (A) and 7.6 6 1.4 (B), res
FIG. 3. The N- and C-termini of Tat are required for transactivation o
nd D2-36 Tat. (B) Bar graph showing the quantitative effects of Tat a
ctivities from three identical experiments performed in duplicate wer
ndicate S.E.M.. The averaged fold transactivation 6 S.E.M. for wt Tat,ig. 2A)) and in Jurkat cells (;8-fold; Fig. 2B). In both cell
ines, transactivation of the Bcl-2 promoter by Tat was
ose dependent (data not shown), being maximal at the
oncentration shown (Fig. 2).
he N- and C-terminal amino acid residues of Tat are
equired for transactivation of the Bcl-2 promoter
Results with the D2-36 mutant of Tat described above
uggested that the N-terminus of Tat is required for Tat-
ediated transactivation of Bcl-2 promoter-directed gene
rkat cell lines. Fold activation was calculated from a ratio of averaged
Tat mutant D2-36 (arbitrarily set at a value of 1). Fold transactivation 6
ly.
cl-2 promoter. (A) Schematic representation of wild-type Tat, 1-57 Tat,
mutants on Bcl-2 promoter-directed CAT expression. Averaged CAT
tified using the Fuji Imager MacBAS software version 2.5. Error bars
at, and D2-36 Tat are 17.9 6 3.3, 3.1 6 0.9, and 1, respectively.and Ju
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505TAT TRANSACTIVATION OF Bcl-2xpression (Figs. 2 and 3). The importance of these resi-
ues for Tat transactivation function is consistent with pre-
ious mutagenesis studies defining the functional domains
f Tat that are essential for Tat-mediated transactivation of
he HIV-1 LTR (Rice and Carlotti, 1990a, 1990b).
Unlike the N-terminus of Tat, the C-terminal region of
at containing a glutamine-rich sequence and the RGD
omain had been shown previously to be dispensable
or transactivation of the HIV-1 LTR. Indeed, sequences
pstream of amino acid 57 are both necessary and
ufficient for Tat transactivation of the HIV-1 LTR. To
etermine whether these sequences are similarly dis-
ensable for Tat transactivation of the Bcl-2 promoter,
ransient expression assays were performed that in-
luded an expression vector for a C-terminally truncated
at (1-57 Tat). Surprisingly, results from these experi-
ents indicated that the C-terminal region of Tat was
equired for optimal transactivation of the Bcl-2 promoter
Fig. 3B). Tat and 1-57 Tat transactivated Bcl-2 promoter-
irected gene expression 17- and 2–3 fold, respectively,
ompared with Bcl-2 promoter activity (set arbitrarily at a
alue of 1) in the presence of the control vector (D2-36
at). When an HIV LTR-CAT reporter construct (CD23)
as substituted for the Bcl-2 promoter-CAT construct in
imilarly designed experiments, both wild-type and 1-57
at transactivated LTR-directed CAT expression (data not
hown). These experiments, together with results ob-
ained by others (Rice and Carlotti, 1990a, 1990b), served
o confirm the biological activity of wild-type Tat and 1-57
at in these transient assays. The Tat mutational analy-
es suggested that both N- and C-terminal amino acid
equences of Tat are required for optimal transactivation
f Bcl-2 promoter-directed gene expression.
pecific amino acids within the activation domain of
at are critical for Tat transactivation of the Bcl-2
romoter
Previous mutagenesis studies defined the activation
omain of Tat in the transactivation of the HIV-1 LTR (Rice
nd Carlotti, 1990a, 1990b; Yang et al., 1997). For exam-
le, glycine substitution for cysteine residues at posi-
ions 22 (C22G) or 30 (C30G) abrogates Tat-mediated
ransactivation of the HIV-1 LTR, whereas a similar sub-
titution at the cysteine residue at position 31 (C31G)
mpairs but fails to totally inhibit transactivation. Alanine
ubstitution mutants Y26A, H33A, and K41A, as well as
2-36 Tat, that contains an N-terminal deletion of resi-
ues 2-36, fail to fully transactivate HIV-1 LTR-directed
ene expression. Conversely, alanine substitution mu-
ant N24A possesses activity at least equivalent to that of
ild-type Tat. To determine which amino acids within the
ctivation domain of Tat are critical for transactivation of
he Bcl-2 promoter, a panel of site-directed mutants of Tat
ere used in transient expression assays as described
bove. Fold activation was calculated as the ratio of CATctivities observed in the presence of wild-type or site-
irected mutant Tat to that observed with D2-36 Tat, set
rbitrarily at a value of 1. The results demonstrated that
he Tat mutants C30G, Y26A, H33A, K41A, and D2-36
ailed to activate Bcl-2 promoter-directed gene expres-
ion, whereas C31G and N24A activated the Bcl-2 pro-
oter to levels similar to that observed with wild-type Tat
Fig. 4). Although Cys22 activated the Bcl-2 promoter, the
evels observed were fivefold less than that seen with
ild-type Tat (Fig. 4). Because these mutants have been
hown previously to be expressed in cells at levels
imilar to that of wild-type Tat (Rice and Carlotti, 1990a),
he low level of transactivation observed with particular
at mutants was not due to differences in levels of Tat
xpression. These results suggested that specific amino
cids within the activation domain of Tat that have been
hown previously to be critical for transactivation of the
IV-1 LTR (Rice and Carlotti, 1990a, 1990b; Yang et al.,
997) are also essential for transactivation of the Bcl-2
romoter.
equences upstream of the Bcl-2 P1 and P2
romoters are required for Tat transactivation
Previous studies have shown that two promoter units,
1 and P2, are responsible for the initiation of Bcl-2
ranscription. The predominantly used promoter, P1, is a
C-rich, TATA-less promoter that displays multiple start
FIG. 4. Specific amino acids within the activation domain of Tat are
ritical for Tat transactivation of the Bcl-2 promoter. Relative CAT ac-
ivities were averaged from three identical transfections performed in
uplicate. Fold transactivation was determined as a ratio of relative
AT activities obtained in the presence of D2-36 Tat, arbitrarily set at a
alue of 1. Error bars indicate S.E.M. Averaged fold transactivation for
t Tat, C22G, N24A, Y26A, C30G, C31G, H33A, and K41A are 17.9 6 3.3,
.4 6 0.9, 13.2 6 3.8, 1 6 0.1, 1.6 6 0.6, 15.4 6 2.7, 1.3 6 0.7, and 1.8 6
.5, respectively.
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506 WANG ET AL.ites and includes seven consensus binding sites for the
ranscription factor Sp1. The second promoter, P2, is
ocated approximately 1.3 kbp downstream from the first.
t includes both a CCAAT box and TATA element and
isplays two discrete initiation sites. This promoter pro-
uces only a small fraction of total Bcl-2 mRNA in the cell
ines studied to date (Seto et al., 1988).
To localize sequences within the Bcl-2 promoter that
ediate responsiveness to Tat transactivation, wild-type
Bcl-2 P) and 59- and/or 39-truncated mutant (TM460-1,
YH 453-21, TM438-2, 38-1, and 38-2) Bcl-2 promoter
eporter constructs (Fig. 5A) were tested in transient
xpression assays for responsiveness to Tat. The P2
romoter region was deleted from the promoter reporter
onstructs Bcl-2P, TM460-1, and MYH453-21 to generate
he 39-truncated Bcl-2-CAT constructs TM438-2, 38-1, and
8-2, respectively (Fig. 5A), that were used in these
ransient expression assays. Fold activation was calcu-
ated based on averaged CAT activities representing
hree identical transfections performed in duplicate in
he presence of HIV-1 Tat relative to values obtained with
he negative control, D2-36 Tat. The results indicated that
he Bcl-2 promoter was no longer responsive to transac-
ivation by Tat when sequences flanked by the HindIII
nd BamHI restriction sites were removed, suggesting
hat the sequences located upstream of the Bcl-2 P1 are
equired for Tat responsiveness (Fig. 5B). In addition, the
oss of upstream P2 promoter sequences (TM438-2)
emonstrated a similar loss in Tat responsiveness. Al-
hough these data fail to define a Tat-responsive element
ithin the Bcl-2 promoter, they suggest that both P1 and
2 may be required for optimal Tat transactivation.
FIG. 5. Sequences upstream of both P1 and P2 promoters are requi
Bcl-2 P) and deletion mutant (TM460-1, MYH453-21, TM438-2, 38-1, and
old activation was calculated as a ratio (wt Tat/D2-36) from averaged re
veraged fold transactivation for Bcl-2 P, TM460-1, MYH453-21, TM438-
0.3, 60.4, 60.8, 61.1, and 60.5, respectively.DISCUSSION
Apoptosis has been suggested to be one of the major
echanisms of CD41 T cell depletion in HIV-1-infected
ndividuals (Ameisen, 1992; Fauci, 1993). Interestingly,
IV-1-infected cells appear to be protected from apopto-
is, whereas apoptosis is induced in uninfected by-
tander cells in the lymph nodes of infected individuals
Nardelli et al., 1995). HIV-1 Tat appears to have a dual
ole in the regulation of apoptosis in T cells in that
xogenous Tat protein induces apoptosis in uninfected T
ells, whereas stable expression of Tat in T cells protects
he cells from apoptosis (McCloskey et al., 1997). The
echanism by which endogenous Tat antagonizes apo-
tosis is unknown, but in some cases, it is correlated
ith increased levels of Bcl-2 (Zauli et al., 1995). These
bservations are consistent with those from other sys-
ems in which apoptosis of virally infected cells is inhib-
ted (Geiger et al., 1995; Henderson et al., 1991). These
tudies collectively suggest the existence of a Bcl-2
nduction pathway that may be mediated by viral and/or
ellular gene expression. Induction of Bcl-2 may be fa-
orable for the survival of active virus-producing cells
Chen et al., 1996; Okan et al., 1995). Contrary to defining
putative antiapoptotic role for endogenously expressed
at, another report demonstrates that expression of Tat
n lymphoid cell lines induces apoptosis induced by
erum deprivation and results in reduced steady-state
evels of Bcl-2 (Sastry et al., 1996). Experiments have
een performed within the study presented here to dis-
ern between these apparently disparate effects of Tat
n the regulation of Bcl-2.
In this study, Tat-expressing HeLa cells contain higher
Tat transactivation of Bcl-2. (A) Schematic representation of wild-type
cl-2 promoters. (B) Quantitative results from Bcl-2 promoter analyses.
AT activities from three identical transfections performed in duplicate.
, and 38-2 are 17.9, 0.7, 1.1, 1.6, 2.6, and 0.8 with S.E.M. values of 63.0,red for
38-2) B
lative C
2, 38-1
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507TAT TRANSACTIVATION OF Bcl-2ndogenous Bcl-2 levels than do control cells that do not
xpress Tat. This difference suggests that HIV-1 Tat ex-
ressed within cells may increase Bcl-2 gene expres-
ion. Transient expression assays demonstrate that
IV-1 Tat activates Bcl-2 promoter-directed gene expres-
ion in HeLa cells (.17-fold) and in Jurkat cells (.7-fold).
nterestingly, both the N- and C-termini of Tat are re-
uired for optimal transactivation. Specific amino acids
ithin the activation and core domains of Tat, including
ys22, Tyr26, Cys30, His33, and Lys41, are critical for Tat
ransactivation of the Bcl-2 promoter. These findings con-
irm and extend earlier observations of Tat-mediated
ransactivation of Bcl-2 expression in Jurkat cells (Zauli et
l., 1995). The sixfold reduction in transactivation of Bcl-2
romoter-directed gene expression observed on C-ter-
inal truncation of Tat (1-57 Tat) suggests that the mech-
nisms that regulate transactivation of the HIV-1 LTR and
he Bcl-2 promoter may differ because these C-terminal
mino acid residues (58–86) of Tat are dispensable for
ctivation of the HIV-1 LTR.
The structure of the bcl-2 gene is complex, and its
romoter structure is poorly characterized. The 59-regu-
atory region of bcl-2 contains two promoter regions: P1
nd P2. The major promoter, P1, is located 1386–1423 bp
pstream of the translation start site. P1 is a TATA-less,
C-rich promoter containing multiple transcription initi-
tion sites as determined by primer extension analyses
Seto et al., 1988). The second promoter, P2 is located
pproximately 1.3 kb downstream of P1 and contains a
anonical TATA element, an octamer motif (ATGCAAAG),
nd a CAAT box (Seto et al., 1988). Little is known about
he molecular mechanisms of bcl-2 transcriptional regu-
ation. Transcription regulators of bcl-2 include the tumor
uppressor protein p53 (Miyashita et al., 1994), the
ilms’ tumor gene product wt1 (Heckman et al., 1997;
ewitt et al., 1996), the paired box transcription factor
AX8 (Hewitt et al., 1997), the POU family transcription
actor Brn-3a (Smith et al., 1998), a member of the imme-
iate–early growth response gene family, Egr-1 (Huang
t al., 1998), and both viral and cellular myb gene prod-
cts (Frampton et al., 1996; Taylor et al., 1996). In addi-
ion, bcl-2 promoter recognition sequences have been
dentified for Sp1, CREB, and p1 (Chen and Boxer, 1995;
ilson et al., 1996; Young and Korsmeyer, 1993).
In an effort to map the location of sequences within the
cl-2 promoter region that are required for Tat-mediated
p-regulation, several 59-truncated Bcl-2 promoters were
nalyzed in transient expression assays. The results
emonstrated that removal of a distal 0.9-kb HindIII–
amHI fragment (24.6 kb to 23.7 kb relative to the
ranslation start site) or a larger fragment containing this
.9-kb sequence (24.6 kb to 21640 bp) abrogated Tat
ransactivation. Recognition sequences for putative cel-
ular or viral transcriptional regulators have yet to be
dentified within this 0.9-kb fragment. In addition, the
utant Bcl-2 promoter lacking P2 yet maintaining theistal 0.9-kb HindIII–BamHI fragment (TM438-2) also
ailed to be activated by Tat, suggesting that the P2 may
lso be required for Tat transactivation. Conceivably, the
2 promoter may be targeted by HIV-1 Tat via the 0.9-kb
pstream responsive sequences even though they are
eparated by several kilobases. Removal of either the
.9-kb fragment or the P2 promoter abolishes Tat effects
n Bcl-2 promoter-directed gene expression. Critical to
he interpretation of these results is the possibility that
mportant initiation sites for P1 in TM438-2, 38–1, and
8–2 promoter mutants may have been removed along
ith the P2 region.
The physiological significance of the observations pre-
ented herein on HIV-1 pathogenesis remains to be
stablished. However, these studies demonstrate that
IV-1 Tat directly or indirectly transactivates Bcl-2, a
ellular gene known for its ability to antagonize apopto-
is and to maintain cellular viability. Determining the
olecular mechanism or mechanisms for Tat transacti-
ation of Bcl-2 is the focus of our future studies.
MATERIALS AND METHODS
lasmids
Wild-type and mutant Tat (C22G, N24A, Y26A, C30G,
31G, H33A, K41A, and 1-57) cDNAs (derived from HXB2
roviral clone) cloned in pGEM-1 expression vectors
ere provided generously by Andrew Rice. The Tat cDNA
ere subsequently subcloned downstream of the human
ytomegalovirus (CMV) immediate–early promoter in the
CMV 12S expression vector (Morris and Mathews, 1991)
etween the EcoRI and HindIII sites, replacing E1A 12S
equences with Tat-specific sequences. The expression
ector pCMV12S.FS contains a frameshift mutation within
1A 243R coding sequences, is unable to generate func-
ional E1A protein, and thus served as a negative control.
he D2-36 was constructed by cloning a Tat-specific PCR
ragment downstream of the CMV promoter in pcDNA3
InVitrogen) under the control of human CMV major in-
ermediate–early promoter. The forward primer (59-GCC-
TCGGTACCATGTGTTTCATAACAAAAGCC-39) and the
everse primer (59-GCATGTGGGCCCGGATCCCTATCTA-
ATTCCTTCGGGCCTGTCG GGTCC-39) were used to
mplify HIV-1 tat sequences (underlining indicates re-
triction enzyme site). The PCR product containing a
eletion of amino acid residues 2-36 was digested with
pnI and ApaI, gel-purified, and then cloned into the
ulticloning site of the pcDNA3 vector. All constructs
ere confirmed by DNA sequencing. Bcl-2 promoter con-
tructs used in this study (P18-21, TM460-1, MYH453-21,
M438-2, 38-1, and 38-2) were described previously
Harigai et al., 1996).
ell lines
HeLa cells (ATCC CCL 2) and Jurkat cells E6–1 (ATCC
IB 152) were purchased from American Type Culture
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508 WANG ET AL.ollection. HeLa cells stably transformed with an HIV-1
TR-CAT reporter construct (LTR-Tat) or an HIV-1 LTR-Tat
xpression vector (LTR-Tat) were provided generously by
he National Institutes of Health AIDS Research and
eference Reagent Program [reagents: HL3T1 cells
LTR-CAT) cells and HLtat (LTR-Tat) cells]. Monolayer
eLa cells were grown in DMEM supplemented with
0% FCS and 100 mg/ml each of penicillin and strepto-
ycin. Jurkat cells were cultured in RPMI 1640 medium
ontaining 10% FCS and 100 mg/ml each of penicillin and
treptomycin. These cell lines were incubated at 37°C in
he presence of 5% CO2.
estern blot analyses
Total cell lysates were prepared from transformed
eLa cells LTR-CAT or LTR-Tat) and Tat-expressing HeLa
ells grown in DMEM supplemented with 10% FCS. Sub-
onfluent cells from a single T-75 flask were lysed in 1 ml
f lysis buffer (25 mM Tris–HCl, pH 7.5, 150 mM, 1% Triton
-100, 1 mM PMSF, and 1 mM aprotinin). Cell debris was
elleted by centrifugation at 14,000 rpm at 4°C. Super-
atants were collected and stored at 220°C. For elec-
rophoresis, the same amount of protein from individual
amples was mixed with 23 SDS–PAGE sample loading
uffer (Harlow and Lane, 1988) and heated at 95°C for 10
in. Samples were resolved by 12% SDS–PAGE and
lectrotransferred to Immune-Lite membranes (Bio-Rad)
r nylon membranes for 1 h at 60 V. Membranes were
locked by incubation in a solution containing 20 mM
ris–HCl and 500 mM NaCl, pH 7.5, 3% gelatin for 1 h at
oom temperature. The blocked membranes were incu-
ated subsequently in a solution containing 20 mM Tris–
Cl, 500 mM NaCl, pH 7.5, 3% gelatin, and 1:3000 diluted
nti-human Bcl-2 mouse monoclonal antibody (320 ng/
l) directed against amino acids 41–54 of human Bcl-2
DAKO) for 1 h at room temperature. After washing of the
embrane three times with buffer containing 20 mM
ris–HCl, 500 mM NaCl, and 0.1% Tween 20, the mem-
ranes were incubated in a solution (20 mM Tris–HCl,
00 mM NaCl, pH 7.5, 3% gelatin) containing goat anti-
ouse antibody conjugated with alkaline phosphatase
1:5000) for 1 h at room temperature with gentle agitation.
he secondary antibody solution was discarded, and the
embranes were washed three times with 20 mM Tris–
Cl and 500 mM NaCl containing 0.1% Tween 20. Finally,
he membranes were immersed in chemiluminescent
ubstrate solution (Bio-Rad) for 5 min and wrapped im-
ediately with plastic wrap. The blots were exposed to
-ray film at room temperature for 2–5 min.
ransfections
Transfection of HeLa cells was performed by the cal-
ium phosphate method (Yang et al., 1997). Briefly, a
ypical transfection mix for one 60-mm tissue culture
late of 60–70% confluent HeLa cells contained 5 mg ofBcl-2 promoter CAT reporter construct and 1 mg of
at-expressing plasmid. Herring sperm DNA was added
o adjust the total amount of DNA for each transfection to
0 mg in 0.25 ml of 23 HBS (1.5 mM Na2HPO4, 10 mM
Cl, 280 mM NaCl, 12 mM glucose, 50 mM HEPES, pH
.0). The DNA mixture was precipitated by adding 0.25 ml
f 0.32 M CaCl2 in a dropwise manner within 30 s
ollowed by a 7-min incubation at room temperature. The
recipitate was then applied to HeLa cells in 60-mm
ishes. The medium was changed 16 h after transfection,
nd the transfected HeLa cells were washed twice with
ml of PBS. HeLa cells were refed with 5 ml of DMEM
ontaining 10% FCS and incubated in 5% CO2 at 37°C for
n additional 32 h before harvesting.
Jurkat cells were grown in suspension in RPMI 1640
edium supplemented with 10% FCS. Transfection of
urkat cells was performed using a polycationic reagent,
uperfect (Qiagen), essentially according to the manu-
acturer’s protocol. Briefly, the day before transfection,
he culture medium was changed, and cells were grown
o log phase. The cells were added at 7.5 3 106 cells/
0-mm dish in 5 ml of complete RPMI 1640 medium for
ransfection. The p18-21 plasmid (5 mg) and Tat expres-
ion vector (1 mg) were mixed with 150 ml of RPMI 1640
ulture medium without serum and antibiotics. The poly-
ationic reagent (20 ml) was then mixed with the DNA
olution by vortexing for 10 s. The mixture of polycationic
eagent and DNA was incubated for 10 min at room
emperature to allow DNA complex formation. The trans-
ection complexes were added to cell culture dishes in a
ropwise manner. Transfected cells were incubated at
7°C in 5% CO2 incubator and harvested 48 h after
ransfection for CAT assays.
AT assays
CAT assays were performed essentially as previously
escribed (Gorman et al., 1982). Forty-eight hours after
ransfection, cells were washed twice with 2 ml of PBS.
ells were pelleted by centrifugation and resuspended
n 100 ml of ice-cold 0.25 M Tris–HCl buffer (pH 8.0). The
esuspended cells were lysed by three freeze–thaw cy-
les at 270°C and 37°C, respectively. Cell debris was
elleted by centrifugation at 14,000 rpm for 5 min at 4°C.
upernatants of cell lysates were collected and stored at
70°C for CAT assays. Cell extracts (50 ml) were ana-
yzed for CAT activity in 100-ml reactions that were incu-
ated at 37°C for 1 h. CAT reactions were stopped by the
ddition of ethyl acetate and vortexed for 30 s. The
rganic solvent was separated from the aqueous phase
y centrifugation at 14,000 rpm for 1 min. The organic
olvent containing acetylated and nonacetylated forms of
4C-chloramphenicol was collected, lyophilized, redis-
olved in 10 ml of ethyl acetate, and spotted onto thin-
ayer chromatography plates. The various acetylated
orms of chloramphenicol were separated by thin-layer
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509TAT TRANSACTIVATION OF Bcl-2hromatography, and the different forms were quantified
ith a Fuji Imager using MacBAS v. 2.5 software pro-
ram. CAT activities were normalized to total protein
ithin the cell extracts as measured by protein assays
Harlow and Lane, 1988). Unless indicated otherwise, the
elative CAT activities represent a average of three iden-
ical transfections performed in duplicate.
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